Dan joined MindMed as Chief Medical Officer in February 2021 following MindMed’s acquisition of HealthMode, the company he co-founded and led as CEO.
Prior to HealthMode, he built and led clinical, informatics, and regulatory strategy for Pfizer’s Digital Medicine and Innovation Research Lab. He also served as Global Clinical Lead for psychiatry clinical compounds at Pfizer. He previously served as founder and Chief Medical Officer at Column Health, a leading technology-enabled psychiatry and addiction practice. He is a strategic advisor to several pharmaceutical, biotech, and health technology companies. He is also a founding Advisor to the Digital Biomarkers Journal, co-founder and Board Chair of the Digital Medicine Society (DiMe), and was on the committee for Leadership for Digital Drug Development Tools at Critical Path Alzheimer’s Disease, MJFF, and Mental Health IT at the APA.
Dan is Board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is a Fellow of the APA and the American Society of Addiction Medicine and an Assistant Professor of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.
What is Daniel Karlin's net worth?
The estimated net worth of Daniel Karlin is at least $8.05 million as of December 26th, 2025. Dr. Karlin owns 425,025 shares of Definium Therapeutics stock worth more than $8,049,974 as of March 27th. This net worth approximation does not reflect any other investments that Dr. Karlin may own. Learn More about Daniel Karlin's net worth.
How do I contact Daniel Karlin?
Has Daniel Karlin been buying or selling shares of Definium Therapeutics?
Daniel Karlin has not been actively trading shares of Definium Therapeutics during the past quarter. Most recently, Daniel Karlin sold 5,600 shares of the business's stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a transaction totalling $73,640.00. Following the completion of the sale, the insider now directly owns 425,025 shares of the company's stock, valued at $5,589,078.75. Learn More on Daniel Karlin's trading history.
Who are Definium Therapeutics' active insiders?
Are insiders buying or selling shares of Definium Therapeutics?
During the last twelve months, insiders at the sold shares 9 times. They sold a total of 133,276 shares worth more than $1,310,205.88. The most recent insider tranaction occured on December, 26th when insider Daniel Karlin sold 5,600 shares worth more than $73,640.00. Insiders at Definium Therapeutics own 2.3% of the company.
Learn More about insider trades at Definium Therapeutics. Information on this page was last updated on 12/26/2025.
